XORTX Therapeutics (XRTX) has received shareholder approval for a consolidation of up to five pre-consolidation common shares for each post-consolidation share, pending approval from the TSX Venture Exchange. This strategic move aims to ensure compliance with Nasdaq’s minimum share price requirement of $1.00, a critical threshold for maintaining its listing.
The consolidation will significantly reduce the company’s outstanding shares from approximately 6.96 million to around 1.39 million, with fractional shares either canceled or rounded up. Following this announcement, XRTX shares surged 6.70% in after-hours trading, reaching $0.4108, reflecting positive investor sentiment regarding the consolidation.
For market professionals, the key takeaway is that this consolidation could enhance XORTX’s market perception and stability, potentially attracting new investors and improving liquidity as it seeks to meet Nasdaq’s listing standards.
Source: seekingalpha.com